Lineage plasticity is the ability of a cell that has already committed to a specific identity and function to switch tracks and become a different type of cell. In normal development, cells follow increasingly narrow paths: a skin cell stays a skin cell, a gut cell stays a gut cell. Lineage plasticity breaks that rule. It can be a lifesaver when tissues need emergency repair, but it also gives cancer cells a way to dodge therapies designed to kill them. The concept sits at the intersection of regeneration, cancer biology, and aging, and understanding it has become one of the more urgent projects in biomedical research.
The Basic Idea Behind Cell Identity Switching
During embryonic development, cells progressively specialize. A fertilized egg can become any cell type in the body, but as it divides and its descendants receive molecular signals, each daughter cell narrows its options. A cell destined for the liver commits to liver-related programs; a cell heading toward the brain adopts neural programs. By adulthood, most cells are locked into their roles. Lineage plasticity is what happens when that lock gets picked.
There are two main routes a cell can take when it changes identity. In dedifferentiation, a mature cell rewinds its developmental clock and reverts to a more primitive, stem-cell-like state. From there, it can re-specialize, sometimes into a completely different cell type. In transdifferentiation, a cell skips the rewind step and converts directly from one mature identity to another. Both routes have been documented in living organisms, both in healthy tissues and in tumors.
The triggers that unlock plasticity include severe tissue damage, inflammation, low oxygen, and the loss of key tumor-suppressor genes. In cancer, drug treatment itself can push cells toward identity switches. Notably, many of the same stresses that promote plasticity in healthy tissue, like chronic injury and inflammation, are also hallmarks of cancer.
How Cells Actually Change Their Identity
Your DNA sequence does not change when a cell switches lineage. What changes is which genes are turned on and which are turned off. The molecular machinery responsible for this involves layers of chemical modifications sitting on top of DNA, collectively called the epigenome. Certain protein complexes act as gatekeepers of gene access: some keep genes locked away, while others pry them open. The interplay between these opposing complexes, along with the reprogramming of regulatory DNA regions called enhancers, can reshape a cell’s gene-activity profile and effectively rewrite its identity.1FEBS Letters. Epigenetic reprogramming of lineage switching in cancer
A special class of proteins called pioneer transcription factors plays a critical early role. Most regulatory proteins can only access genes that are already somewhat exposed. Pioneer factors are different: they can latch onto tightly packed, silent stretches of DNA and begin loosening them, making those genes available for activation for the first time. This pioneering activity is essential both in normal embryonic development and in artificial cell reprogramming.2PubMed Central. Pioneer transcription factors, chromatin dynamics, and cell fate control
Non-coding RNAs add yet another control layer. These are RNA molecules that do not encode proteins but instead regulate gene activity. In melanoma, for example, various types of non-coding RNAs have been shown to influence the plasticity programs that drive tumor progression, drug response, and resistance.3PubMed Central. Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response The emerging picture is that lineage plasticity is not governed by a single switch but by overlapping layers of gene regulation, all of which must shift in concert for a cell to truly change what it is.
Plasticity as a Repair Strategy in Healthy Tissue
Lineage plasticity is not inherently a disease process. In fact, some of our organs depend on it for day-to-day maintenance and emergency repair. The intestinal lining is one of the best-studied examples. The traditional view held that intestinal stem cells, housed in small pockets called crypts, were the sole source of new cells. Damage to those stem cells would be catastrophic. But research has shown that the system is far more resilient than that. When stem cells are destroyed, other already-specialized cells in the crypt can revert to a stem-cell-like state and regenerate the entire epithelium.4PubMed Central. Intestinal epithelial plasticity and regeneration via cell dedifferentiation
Experiments in mice have shown that both absorptive and secretory precursor cells in the gut can dedifferentiate to restore the stem cell pool after injury. When one of these cell types is missing, the other can step in and do the job. The process depends on specific transcription factors that essentially re-activate the stem cell program in cells that had already moved past it.5Cell Stem Cell. ASCL2-Dependent Crypt Cell Plasticity Enables Intestinal Stem Cell Restoration This kind of built-in redundancy gives the gut remarkable resilience against damage from infection, toxins, or radiation.
Transdifferentiation in the Pancreas
One of the most medically exciting examples of lineage plasticity involves the pancreas. In type 1 diabetes, the immune system destroys the insulin-producing beta cells, and current treatments revolve around replacing the lost insulin externally. But the pancreas also contains alpha cells, which produce a different hormone called glucagon. Researchers have been exploring whether alpha cells can be coaxed into becoming insulin-producing beta cells, effectively refilling the depleted stock from within the organ itself.6PubMed Central. Alpha-to-beta cell trans-differentiation for treatment of diabetes
In one series of mouse experiments, researchers used a viral delivery system to introduce two transcription factors into the pancreas of mice whose beta cells had been chemically destroyed. Within two weeks, the treated mice had their blood sugar corrected. By four weeks, beta cell mass had recovered to more than 60% of normal levels. Tracing the origin of the new beta cells confirmed that roughly 79% of them had come from alpha cells that switched identity.7Cell Stem Cell. In Vivo Reprogramming of Alpha to Beta Cells in the Adult Pancreas This is still far from a human therapy, but it demonstrates that adult cells in a living animal can be pushed across lineage boundaries with just a couple of molecular nudges.
When Cancer Hijacks Plasticity
The same flexibility that lets healthy tissues repair themselves becomes dangerous when tumors exploit it. Lineage plasticity has emerged as a major mechanism by which cancers develop resistance to targeted therapies. The basic story: a drug targets a specific molecular feature that the cancer depends on, and instead of dying, the cancer cells switch to a different identity that no longer relies on that feature.8PubMed Central. Lineage plasticity in cancer: a shared pathway of therapeutic resistance
This pattern has now been documented across several cancer types. Two of the clearest examples are prostate cancer and lung cancer.
Prostate Cancer and Neuroendocrine Transformation
Standard treatment for advanced prostate cancer targets the androgen receptor, which the tumor relies on for growth signals. In a subset of patients, prolonged hormone therapy triggers a shift: the cancer cells stop expressing the androgen receptor entirely and take on a neuroendocrine identity, a cell type that normally belongs in the nervous system and has nothing to do with prostate function. This neuroendocrine prostate cancer is far more aggressive and, because it no longer depends on androgen signaling, is effectively invisible to the drugs designed to block it.9PubMed Central. Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer
Lung Cancer and Small Cell Transformation
A strikingly similar process occurs in lung adenocarcinoma driven by mutations in the EGFR gene. Patients treated with targeted drugs that block EGFR signaling sometimes see their tumors transform into small cell lung cancer, a histologically and behaviorally distinct disease. The transformed cancer retains the original EGFR mutation but dramatically reduces EGFR protein levels, rendering the targeted drug useless. This transformation occurs in roughly 3 to 14 percent of cases and carries a poor prognosis because the new tumor type is highly aggressive and resistant to conventional treatments.10PubMed. Transformation from EGFR-mutant lung adenocarcinoma to small-cell lung cancer: from clonal evolution to lineage reprogramming
What makes this pattern so challenging is that the transformation is not a genetic mutation in the traditional sense. The DNA sequence may barely change. Instead, the cancer rewires its gene-regulation programs to adopt a completely different cellular identity, one that happens to be resistant to the therapy that was working. It is an epigenetic escape route, and the drug itself seems to be part of what selects for it.11PubMed. Small cell lung cancer transformation: From pathogenesis to treatment
Melanoma and Phenotype Switching
Melanoma provides another well-studied window into tumor plasticity, though it plays out somewhat differently than the prostate and lung examples. Melanoma cells have been found to toggle between two states: one geared toward proliferation and one geared toward invasion. Expression profiling has identified distinct molecular signatures for each state, and tumor cells appear to switch between them in living tissue.12Cancer Research. In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States This means a melanoma tumor may not be a fixed entity; instead, its cells could be continuously flipping between growing in place and spreading to other organs. Therapeutic strategies that target only the proliferative state might inadvertently enrich for invasive cells, and vice versa.
The metabolic dimensions of this switching are also coming into focus. Cancer cells appear to reprogram their metabolism to support whatever new phenotypic state they are transitioning into, whether that involves maintaining stem-cell-like properties, activating invasion programs, or surviving drug exposure.13PubMed Central. Shifting the Gears of Metabolic Plasticity to Drive Cell State Transitions in Cancer Plasticity, in other words, is not just about gene regulation. It extends to how cells fuel themselves.
The Yamanaka Experiment and Artificial Plasticity
The modern understanding of lineage plasticity owes a great deal to a landmark experiment from 2006. Shinya Yamanaka and his team showed that ordinary mouse skin cells could be pushed all the way back to a state resembling embryonic stem cells by introducing just four transcription factors. These induced pluripotent stem (iPS) cells could then be coaxed to become almost any cell type in the body.14PubMed. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors The same approach was soon replicated with adult human skin cells using the same four factors.15PubMed. Induction of pluripotent stem cells from adult human fibroblasts by defined factors
This was a proof of concept that cell identity is not permanently fixed by irreversible changes to DNA. Instead, identity is maintained by potentially reversible patterns of gene regulation. If you supply the right transcription factors, you can override those patterns and reset the cell. The discovery won Yamanaka the Nobel Prize in 2012 and fundamentally reshaped how biologists think about commitment and fate. It also raised an uncomfortable question: if a small set of transcription factors can reprogram a normal cell in a dish, could something similar happen spontaneously in the body, especially under stress? The cancer plasticity research described above suggests the answer is yes.
Plasticity in Other Organisms
Lineage plasticity is not unique to mammals. Some of the most dramatic examples come from species famous for their regenerative abilities. The axolotl, a salamander that can regrow entire limbs, relies heavily on dedifferentiation. When an axolotl loses a limb, mature connective tissue cells at the wound site revert to a progenitor state that resembles the cells found in an embryonic limb bud. From that reset state, they can re-specialize to form cartilage, tendons, and other tissues needed to rebuild the limb.16PubMed Central. Single-cell analysis uncovers convergence of cell identities during axolotl limb regeneration Transplantation experiments have further confirmed that axolotl connective tissue cells dedifferentiate and then reintegrate into multiple lineages during regeneration.17PubMed Central. Fibroblast dedifferentiation as a determinant of successful regeneration
Plants take plasticity even further. When plant tissue is damaged or placed in culture, cells can form a mass of dedifferentiated tissue called a callus. A subset of these callus cells acquire something close to pluripotency, meaning they can generate entirely new shoots, roots, and eventually a whole new plant. This extraordinary capacity for regeneration is one reason why plants can be propagated from cuttings and why tissue culture is such a powerful tool in agriculture and research.18PubMed Central. Insights into plant regeneration: cellular pathways and DNA methylation dynamics The underlying molecular logic shares surprising parallels with animal plasticity, including reliance on changes to DNA methylation patterns to unlock new developmental programs.
Aging and the Erosion of Cell Identity
An emerging area of research asks what happens to lineage fidelity as organisms age. The basic premise is intuitive: if plasticity is triggered by tissue damage, inflammation, and stress, and aging involves decades of accumulated damage, then aged tissues might show more identity drift than young ones. There is growing evidence that this is exactly what happens. Older cells appear more prone to losing their established identity, whether through partial dedifferentiation, biased differentiation into the wrong cell type, or acquisition of features that belong to a different lineage entirely.19PubMed. A cellular identity crisis? Plasticity changes during aging and rejuvenation
This age-related erosion of cell identity may contribute to diseases commonly associated with aging, including neurodegeneration and cancer. A neuron that starts expressing genes from a non-neural lineage may function poorly. A liver cell that partially dedifferentiates may be one step closer to becoming a tumor cell. The connection between aging and plasticity also suggests that rejuvenation strategies, some of which deliberately invoke partial reprogramming using factors related to those Yamanaka discovered, carry inherent risks: push the reset too far, and you may trigger cancer rather than reverse aging.
Tracking Plasticity in Real Time
One reason lineage plasticity went underappreciated for so long is that it is technically difficult to catch cells in the act of switching. Traditional pathology looks at a snapshot: here is what the tumor looks like today. It cannot tell you whether the small cell lung cancer in a biopsy descended from the adenocarcinoma that was there last year. New tools are changing that. Lineage tracing, which involves genetically tagging cells so that all their descendants carry a permanent, heritable marker, allows researchers to track which cells gave rise to which.
In a mouse model of lung adenocarcinoma, researchers combined an evolving lineage-tracing system with single-cell RNA sequencing to follow tumors from single transformed cells all the way to metastatic disease. They found that loss of the tumor’s initial stable identity was accompanied by a transient burst of increased plasticity, a window during which cells explored new identities before settling into more aggressive states.20PubMed Central. Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution Similar single-cell approaches are now being applied to cardiovascular remodeling, where endothelial cells lining blood vessels appear to undergo identity shifts during disease.21European Heart Journal. Integrating single-cell sequencing and genetic lineage tracing reveals endothelial plasticity during atrial remodeling
These methods are turning what used to be a static before-and-after comparison into a dynamic movie. They are also revealing that plasticity is not an all-or-nothing event. Cells can occupy intermediate states, expressing markers from two lineages at once, or hover in a progenitor-like limbo before committing to a new fate. This messiness makes clinical detection harder but is pushing the field toward more nuanced models of how tissues change over time.
Therapeutic Implications and Open Questions
If plasticity is a key route by which tumors escape targeted therapy, then finding ways to block or reverse plasticity becomes a therapeutic priority. Several strategies are under investigation. Because the identity switch is driven primarily by epigenetic changes rather than permanent DNA mutations, drugs that target epigenetic regulators, such as inhibitors of certain histone-modifying enzymes, are being tested for their ability to lock tumors into a drug-sensitive state.22PubMed Central. The Transcriptional and Epigenetic Landscape of Cancer Cell Lineage Plasticity The logic is straightforward: if you can prevent a prostate adenocarcinoma from becoming neuroendocrine, it stays vulnerable to hormone therapy.
Other approaches focus on monitoring. If a patient’s tumor is beginning to shift identity, early detection of that shift, perhaps through liquid biopsy markers, might allow clinicians to switch treatments before full resistance develops. The challenge is that the same plasticity programs that drive resistance are also intertwined with immune evasion and metabolic reprogramming, meaning that truly effective anti-plasticity therapy may need to hit multiple targets at once.
On the regenerative side, understanding how the gut, the pancreas, and organisms like the axolotl harness plasticity for repair opens possibilities for tissue engineering and cell therapy. The alpha-to-beta cell conversion in mice is still years away from clinical application, but it represents a fundamentally different approach to diabetes than injecting insulin or transplanting donor cells. Instead of replacing the missing cells from outside, you would coax the patient’s own body to grow them from nearby cells that are already there. The gap between that concept and a workable human therapy remains wide, but the biological plausibility has been established, and the molecular tools for achieving it are becoming more precise every year.